Early investigational tubulin inhibitors as novel cancer therapeutics
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Early investigational tubulin inhibitors as novel cancer therapeutics
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 25, Issue 8, Pages 917-936
Publisher
Informa UK Limited
Online
2016-05-18
DOI
10.1080/13543784.2016.1189901
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Larotaxel (L) in combination with trastuzumab in patients with HER2 + metastatic breast cancer (MBC): Interim analysis of an open phase II label study
- (2017) V. Dieras et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel tubulin inhibitor ALB 109564(a) in patients with solid tumors: A phase I trial.
- (2017) M. S. Clancy et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel strategy to identify drugs that delay relapse.
- (2017) M. Hall et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of paclitaxel poliglumex (PPX), temozolamide (TMZ), and radiation (RT) for newly diagnosed high-grade gliomas.
- (2017) S. A. Jeyapalan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
- (2016) Do-Youn Oh et al. Cancer Research and Treatment
- Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies
- (2015) Olivier Rixe et al. ANTI-CANCER DRUGS
- Antimitotic and antivascular activity of heteroaroyl-2-hydroxy-3,4,5-trimethoxybenzenes
- (2015) Hsueh-Yun Lee et al. BIOORGANIC & MEDICINAL CHEMISTRY
- A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma
- (2015) S. Pal et al. CLINICAL CANCER RESEARCH
- Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
- (2015) Ya-Ting Ji et al. CURRENT MEDICINAL CHEMISTRY
- A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma
- (2015) Deanna Mitchell et al. PEDIATRIC BLOOD & CANCER
- A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours
- (2014) F A L M Eskens et al. BRITISH JOURNAL OF CANCER
- Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors
- (2014) Rastislav Bahleda et al. INVESTIGATIONAL NEW DRUGS
- The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization
- (2014) Andrea E. Prota et al. JOURNAL OF MOLECULAR BIOLOGY
- DISRUPT: A randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane–platinum regimen as first-line therapy for metastatic non-small cell lung cancer
- (2014) Joachim von Pawel et al. LUNG CANCER
- Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program
- (2014) E. Anders Kolb et al. PEDIATRIC BLOOD & CANCER
- A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer
- (2013) Emmanuel S. Antonarakis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors
- (2013) C. Sessa et al. CLINICAL CANCER RESEARCH
- A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma
- (2013) Anna K. Nowak et al. LUNG CANCER
- Structure Activity Relationship of Arylidene Pyrrolo and Pyrido [2,1-b] Quinazolones as Cytotoxic Agents: Synthesis, SAR Studies, Biological Evaluation and Docking Studies
- (2013) Veenu Mangla et al. Medicinal Chemistry
- Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB)
- (2013) Cora N. Sternberg et al. ONCOLOGY
- Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A report from the Children's Oncology Group (ANBL0621)
- (2013) Elizabeth Fox et al. PEDIATRIC BLOOD & CANCER
- Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents
- (2013) A. E. Prota et al. SCIENCE
- Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
- (2012) J Cummings et al. BRITISH JOURNAL OF CANCER
- Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer
- (2012) P. Nathan et al. CLINICAL CANCER RESEARCH
- Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors
- (2012) Dan M. Patterson et al. CLINICAL CANCER RESEARCH
- Antimitotic Inhibitors
- (2012) Susana M. Campos et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent
- (2012) Matthew Burge et al. INVESTIGATIONAL NEW DRUGS
- The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models
- (2012) Céline Clémenson et al. INVESTIGATIONAL NEW DRUGS
- Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme
- (2012) Kenneth F. Grossmann et al. JOURNAL OF NEURO-ONCOLOGY
- Abstract C232: ALB-109564, a novel tubulin inhibitor with improved efficacy over vinorelbine, is better tolerated when dosed iv versus ip, leading to improved activity in human tumor xenograft studies
- (2012) M. A. Wolf et al. MOLECULAR CANCER THERAPEUTICS
- TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells
- (2012) D. P. Fitzgerald et al. MOLECULAR CANCER THERAPEUTICS
- Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials
- (2012) R. Dienstmann et al. MOLECULAR CANCER THERAPEUTICS
- An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site
- (2012) Yan Lu et al. PHARMACEUTICAL RESEARCH
- Tubulin-Destabilizing Agent BPR0L075 Induces Vascular-Disruption in Human Breast Cancer Mammary Fat Pad Xenografts
- (2012) Li Liu et al. PLoS One
- Neoadjuvant Paclitaxel Poliglumex, Cisplatin, and Radiation for Esophageal Cancer
- (2011) Thomas Dipetrillo et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation
- (2011) D. Rischin et al. CLINICAL CANCER RESEARCH
- Thiazolyl N-benzyl-substituted acetamide derivatives: Synthesis, Src kinase inhibitory and anticancer activities
- (2011) Asal Fallah-Tafti et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation
- (2011) Lotte B. Bertelsen et al. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer
- (2011) Jason E. Faris et al. INVESTIGATIONAL NEW DRUGS
- Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel
- (2011) Michael Millward et al. INVESTIGATIONAL NEW DRUGS
- Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer
- (2011) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a Tubulin Polymerization Inhibitor with Potent Antiproliferative and Tumor Vascular Disrupting Properties
- (2011) Bernard L. Flynn et al. JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis and Structure–Activity Relationship Study of Antimicrotubule Agents Phenylahistin Derivatives with a Didehydropiperazine-2,5-dione Structure
- (2011) Yuri Yamazaki et al. JOURNAL OF MEDICINAL CHEMISTRY
- Isolation and identification of five impurities of ALB 109564(a) drug substance
- (2011) Dennis J. Milanowski et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Disrupting established tumor blood vessels
- (2010) Mark J. McKeage et al. CANCER
- The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents
- (2010) Dietmar W. Siemann CANCER TREATMENT REVIEWS
- Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
- (2010) P. R. Lockman et al. CLINICAL CANCER RESEARCH
- Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas
- (2010) M. M. Mita et al. CLINICAL CANCER RESEARCH
- Identification of CKD-516: A Potent Tubulin Polymerization Inhibitor with Marked Antitumor Activity against Murine and Human Solid Tumors
- (2010) Jaekwang Lee et al. JOURNAL OF MEDICINAL CHEMISTRY
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy
- (2010) G. Kremmidiotis et al. MOLECULAR CANCER THERAPEUTICS
- Microtubule-binding agents: a dynamic field of cancer therapeutics
- (2010) Charles Dumontet et al. NATURE REVIEWS DRUG DISCOVERY
- Microtubule-Binding Natural Products for Cancer Therapy
- (2010) Qing-Xi Yue et al. PLANTA MEDICA
- Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours
- (2009) Nobuyuki Yamamoto et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
- (2009) A. C. Mita et al. CLINICAL CANCER RESEARCH
- Preclinical evaluation of vascular-disrupting agents in Ewing’s sarcoma family of tumours
- (2009) Surita Dalal et al. EUROPEAN JOURNAL OF CANCER
- Long-Term Follow-Up of Cisplatin Combination Chemotherapy in Patients With Disseminated Nonseminomatous Germ Cell Tumors: Is a Postchemotherapy Retroperitoneal Lymph Node Dissection Needed After Complete Remission?
- (2009) Yaron Ehrlich et al. JOURNAL OF CLINICAL ONCOLOGY
- Tubulin-Interactive Natural Products as Anticancer Agents(1)
- (2009) David G. I. Kingston JOURNAL OF NATURAL PRODUCTS
- Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients
- (2009) Jade Homsi et al. MELANOMA RESEARCH
- Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance
- (2009) E. A. Perez MOLECULAR CANCER THERAPEUTICS
- A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome
- (2009) Colin J. Mooney et al. THYROID
- Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy
- (2008) V. Dieras et al. ANNALS OF ONCOLOGY
- Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin®, in resistant solid tumor malignancies
- (2008) Paula M. Fracasso et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity
- (2008) P. Krishnamurthy et al. CANCER RESEARCH
- Vascular targeted therapies in oncology
- (2008) Dietmar W. Siemann et al. CELL AND TISSUE RESEARCH
- In Reply
- (2008) Tomasz M. Beer JOURNAL OF CLINICAL ONCOLOGY
- Medical Care in Long-Term Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study
- (2008) Paul C. Nathan et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II Study of ABT-751 in Patients with Advanced Non-small Cell Lung Cancer
- (2008) Ann M. Mauer et al. Journal of Thoracic Oncology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started